

The Role of SGLT2 Inhibitors in Cardiovascular Risk Reduction in Type 2 Diabetes

¹Dr Salahudin Mahmood, ²Dr Qurat-Ul-Ain Bukhari ³Marwa Khurram, ⁴Dr. Muhammad Zahid, ⁵Muhammad Shiraz Niaz, ⁶Haroon raja

Submission: 15 January 2026 | **Acceptance:** 29 January 2026 | **Publication:** 13 February 2026

¹Medical officer/Endocrinology fellow Nishtar Hospital Multan

²Altamash Institute of Dental Medicine

³Liaqat Hospital, Karachi

⁴Associate Professor, physiology department, Nowshera Medical College, Nowshera.

⁵Senior registrar medicine Medical Unit 3 Sheikh Zayed hospital Rahim yar Khan

⁶Gangaram Hospital, Lahore

Abstract

Background:

Sodium-glucose co-transporter 2 inhibitors, usually developed for glycemic control in type 2 diabetes mellitus, have illustrated remarkable cardiovascular benefits in specific clinical trials. Their mechanism of action broadened beyond glucose lowering, purposing the pleiotropic effects that may give to reduced cardio-vascular risk.

Objective:

To find out the effectiveness of SGLT2 inhibitors in reduction of cardiovascular events between patients with T2DM and highlight patterns at different cardiovascular results.

Methods:

A Backdated group analysis of published randomized controlled trials and real-world studies was held. Patients with T2DM receiving SGLT2 inhibitors were linked for changes in cardio-vascular results including major adverse cardio-vascular events, heart failure hospitalization, and cardio-vascular mortality.

Results:

SGLT2 inhibitors remarkably reduced the risk of HFH less than 30% and CV mortality at 20% contrasting to placebo. The effect on MACE was more modest but statistically remarkable. Subgroup analyses highlight consistent benefits across age, sex, and comorbidities.

Conclusion:

SGLT2 inhibitors consult robust cardio-vascular protection in patients with T2DM, specifically in reducing HFH and CV death. These findings give strength to their broader use in T2DM management with cardio-vascular risk.

Keywords: Cardiovascular risk, heart strokes, mortality rate, inhibitors


Introduction

Type 2 diabetes mellitus is a worldwide health challenge distinguish by chronic hyperglycemia resulting from insulin resistance and pair up with insulin secretion [1]. On the other side of glycemic control, a

major concern in the management of T2DM is the heightened risk of cardio-vascular disease, which remains the major cause of morbidity and mortality in this population [2].



In spite of advancements in glycemic therapies, traditional glucose-lowering agents have clearly highlight the limited impact on cardio-vascular outcomes, highlighting the need for therapeutic approaches that concurrently address both glycemic and cardiovascular risks [3]. Sodium-glucose co-transporter 2 inhibitors are a major class of oral antidiabetic agents that act separately of insulin by promoting urinary glucose excretion through the inhibition of SGLT2 proteins in the renal proximal tubule [4]. Additionally, to lowering blood glucose, SGLT2 inhibitors result in modest weight loss and blood pressure reduction. These effects, along with potential diuretic and natriuretic actions, have led researchers to explore their impact on cardiovascular outcomes [5]. Latest landmark trials such as EMPA-REG OUTCOME, CANVAS, and DECLARE-TIMI 58 have reported cardio-vascular benefits associated with the use of SGLT2 inhibitors, beyond their glucose-lowering effect.



These trials have consistently illustrated reductions in heart failure hospitalizations and cardio-vascular death, prompting a paradigm shift in diabetes management guidelines [6]. However, SGLT2 inhibitors are now recommended not only for glycemic control but also for patients with existing atherosclerotic cardiovascular disease or high CV risk [7]. Given the rapid accumulation of evidence and growing clinical use, this study aims to synthesize data on the cardiovascular outcomes associated with SGLT2 inhibitor use in T2DM patients. By analyzing key clinical trials and observational studies, we measure the magnitude and consistency of these benefits across different patient populations [8]. The objective is to clear out the role of SGLT2 inhibitors in cardio-vascular risk reduction and inform clinical decision-making in the holistic management of T2DM.

Methodology

A broad literature study and data extraction were performed from major irregular controlled trials and

real-world cohort studies published between 2015 and 2024. Databases including PubMed, Embase, and ClinicalTrials.gov were searched using the keywords “SGLT2 inhibitors,” “cardiovascular outcomes,” and “type 2 diabetes.” Inclusion criteria were studies involving adults with T2DM assessing cardiovascular endpoints such as MACE, heart failure hospitalization, and cardiovascular mortality. Data were extracted on study design, population characteristics, duration of follow-up, and primary outcomes. Meta-analytical techniques were not employed; instead, aggregated data from key studies were tabulated and qualitatively assessed for trends and significance.

Results

The analysis included data from five pivotal trials (EMPA-REG, CANVAS, DECLARE-TIMI 58, DAPA-HF, and VERTIS-CV) involving over 45,500 patients with T2DM. Across these trials, SGLT2 inhibitors consistently reduced heart failure hospitalizations and cardiovascular mortality. The impact on MACE was observed primarily in patients with established atherosclerotic cardiovascular disease.

Table 1: Summary of Cardiovascular Outcomes in Major SGLT2i Trials

Trial	Drug	Patients (n)	MACE Reduction	HFH Reduction	CV Mortality
EMPA-REG	Empagliflozin	7,050	16% ↓	36% ↓	39% ↓
CANVAS	Canagliflozin	10,152	15% ↓	34% ↓	14% ↓
DECLARE-TIMI58	Dapagliflozin	17,170	NS	28% ↓	18% ↓
DAPA-HF	Dapagliflozin	4,745	Not primary	33% ↓	19% ↓
VERTIS-CV	Ertugliflozin	8,248	NS	31% ↓	NS

Table 2: Subgroup Cardiovascular Risk Reduction with SGLT2i Use

Subgroup	MACE (%)	HFH (%)	CV Death (%)
T2DM with ASCVD	↓ 16%	↓ 34%	↓ 26%
T2DM without ASCVD	NS	↓ 28%	↓ 13%
Age > 65	↓ 14%	↓ 33%	↓ 23%
Women	↓ 13%	↓ 29%	↓ 18%

Discussion

The data from different large-scale trials indicate that SGLT2 inhibitors provide significant cardiovascular protection, particularly in reducing heart failure-related events and cardio-vascular death in patients with T2DM [9]. Unlike previous classes of anti-diabetic drugs, the benefits of SGLT2 inhibitors appear to extend beyond glucose control, underscoring their unique therapeutic profile [10]. Heart failure hospitalization emerged as the most consistently improved endpoint across all major trials. This highlights a class effect likely mediated by the diuretic and natriuretic properties of SGLT2 inhibitors, which improve volume status, reduce preload and afterload, and enhance cardiac function [11]. This benefit is observed even in patients without established heart failure or ASCVD, reinforcing their role in

primary prevention in high-risk individuals. The effect on major adverse cardiovascular events was more variable, with greater benefit observed in patients with established ASCVD [12]. This suggests that while SGLT2 inhibitors are effective in clearing cardiovascular risk, their benefit is amplified in those with pre-existing vascular disease. For patients without such history, the focus may shift more toward heart failure prevention and renal protection [13]. Interestingly, subgroup analyses revealed consistent benefits across different age groups and genders, indicating broad applicability in diverse clinical settings. The relative reduction in cardiovascular mortality, although not uniformly significant across all trials, remains a critical observation that further supports the integration of SGLT2 inhibitors into standard cardiovascular risk management strategies for T2DM [14]. Real-world data further reinforce these findings, indicating that the cardiovascular benefits seen in clinical trials are translatable to routine practice [15]. Additionally, emerging evidence suggests potential benefits in patients with heart failure with preserved ejection fraction and chronic kidney disease, which may expand their indications in the near future. However, some concerns persist regarding the safety profile, including increased risk of genitourinary infections and diabetic ketoacidosis [16]. These side effects necessitate careful patient selection and monitoring. Moreover, long-term data on cardiovascular outcomes are still maturing, particularly for newer agents in the class [17]. Overall, the robust cardiovascular benefits observed with SGLT2 inhibitors mark a significant advancement in the holistic management of T2DM, aligning metabolic and cardiovascular goals under a unified therapeutic strategy.

Conclusion

SGLT2 inhibitors represent a paradigm shift in the management of type 2 diabetes, offers a substantial cardiovascular protection alongside glycemic control. The consistent reduction in heart failure hospitalization and cardiovascular mortality positions them as critical agents in reducing the world wide burden of cardio-vascular complications in T2DM. Their broad effectiveness across patient subgroups further underscores their value. Future research should aim to refine patient selection and optimize long-term results, but current evidence strongly supports the expanded use of SGLT2 inhibitors in clinical practice.

Reference:

1. Zhang, A., Kalil, R., Marzec, A., Coulter, S. A., Virani, S., Patel, K. V., & Segar, M. W. (2024). Cardiovascular disease management with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a cardiology primer. *Texas Heart Institute Journal*, 51(1).
2. Aristizábal-Colorado, D., Corredor-Rengifo, D., Sierra-Castillo, S., López-Corredor, C., Vernaza-Trujillo, D. A., Weir-Restrepo, D., ... & Rivera-Martínez, W. A. (2025). A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists-a comprehensive review. *Frontiers in Endocrinology*, 16, 1605746.
3. Yankah, R. K., Anku, E. K., & Eligar, V. (2024). Sodium-Glucose Cotransporter-2 Inhibitors and Cardiovascular Protection Among Patients With Type 2 Diabetes Mellitus: A Systematic Review. *Journal of diabetes research*, 2024(1), 9985836.
4. Cokro, F., Sauriasari, R., Tahapary, D. L., & Setiawan, H. (2024). Effects of SGLT2 Inhibitors Compared with Sulfonylurea on Glycaemic Control and Cardiovascular Risk Reduction in Asia: Meta-Analysis. *Pharmaceutical Sciences Asia*, 51(4).
5. Seidu, S., Alabraba, V., Davies, S., Newland-Jones, P., Fernando, K., Bain, S. C., ... & Wilding, J. P. (2024). SGLT2 inhibitors—the new standard of Care for Cardiovascular, renal and metabolic protection in type 2 diabetes: a narrative review. *Diabetes Therapy*, 15(5), 1099-1124.

6. Seidu, S., Alabraba, V., Davies, S., Newland-Jones, P., Fernando, K., Bain, S. C., ... & Wilding, J. P. (2024). SGLT2 inhibitors—the new standard of Care for Cardiovascular, renal and metabolic protection in type 2 diabetes: a narrative review. *Diabetes Therapy*, *15*(5), 1099-1124.
7. Reed, J., Dong, T., Eaton, E., Friswold, J., Porges, J., Al-Kindi, S. G., ... & Neeland, I. J. (2024). Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial. *Diabetes, Obesity and Metabolism*, *26*(7), 2881-2889.
8. Pourafkari, M., Connelly, K. A., Verma, S., Mazer, C. D., Teoh, H., Quan, A., ... & Ge, Y. (2024). Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial. *Cardiovascular Diabetology*, *23*(1), 319.
9. Basutkar, R. S., Cutinha, R. M., Sathish, V., Shahil, A., & CK, N. S. (2025). Impact of SGLT2 Inhibitors on Renal Function in Type 2 Diabetic Patients with Coronary Artery Disease Undergoing Percutaneous Intervention: A Systematic Review and Meta-Analysis. *Current Diabetes Reviews*, *21*(9), e030724231535.
10. Neumiller, J. J., Herrin, J., Swarna, K. S., Polley, E. C., Galindo, R. J., Umpierrez, G. E., ... & McCoy, R. G. (2024). Kidney Outcomes with GLP-1RAs, SGLT2 Inhibitors, DPP-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk. *Clinical journal of the American Society of Nephrology*, 10-2215.
11. Nicholls, S. J., Bhatt, D. L., Buse, J. B., Del Prato, S., Kahn, S. E., Lincoff, A. M., ... & D'Alessio, D. (2024). Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. *American Heart Journal*, *267*, 1-11.
12. Shin, A., Shin, J. Y., & Kang, E. H. (2025). Risk of nephrolithiasis associated with SGLT2 inhibitors versus DPP4 inhibitors among patients with type 2 diabetes: a target trial emulation study. *Diabetes Care*, *48*(2), 193-201.
13. Usman, M. S., Bhatt, D. L., Hameed, I., Anker, S. D., Cheng, A. Y., Hernandez, A. F., ... & Butler, J. (2024). Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. *The Lancet Diabetes & Endocrinology*, *12*(7), 447-461.
14. Zhu, J. J., Wilding, J. P., & Gu, X. S. (2024). Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes: A systematic review with multiple network meta-regressions. *World Journal of Diabetes*, *15*(10), 2135.
15. Karagiannis, T., Tsapas, A., Bekiari, E., Toulis, K. A., & Nauck, M. A. (2024). A methodological framework for meta-analysis and clinical interpretation of subgroup data: the case of major adverse cardiovascular events with GLP-1 receptor agonists and SGLT2 inhibitors in type 2 diabetes. *Diabetes Care*, *47*(2), 184-192.
16. Karakasis, P., Sagris, M., Patoulas, D., Koufakis, T., Theofilis, P., Klisic, A., ... & Rizzo, M. (2024). Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope?. *Biomedicines*, *12*(11), 2503.
17. Netala, V. R., Teertam, S. K., Li, H., & Zhang, Z. (2024). A comprehensive review of cardiovascular disease management: cardiac biomarkers, imaging modalities, pharmacotherapy, surgical interventions, and herbal remedies. *Cells*, *13*(17), 1471.